20 August 2018
Visiongain’s new report Global Biosimilar Monoclonal Antibodies Forecast 2017-2027: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab indicates that the global biosimilar monoclonal antibodies market will see $4.2bn in spending in 2020.
The global biosimilar monoclonal antibodies market is expected to grow at a CAGR of 9.6% in the second half of the forecast period. The market is expected to grow at a CAGR of 23.8% from 2015-2027. The market is estimated at $4.2bn in 2020 and $7.9bn in 2027.
The lead analyst of the report said: “In 2016, the world market for biosimilar monoclonal antibodies (mAbs) generated revenue of $936.4m, visiongain estimates. Revenue was generated primarily by four biosimilar mAb compounds available in the emerging markets. The market for biosimilar monoclonal antibodies is still in its infancy due to the lack of therapeutic compounds presently off-patent, and the need to prove biosimilarity to reference compounds which are off-patent.
The biosimilar mAbs submarket will be the fastest growing segment of the world biosimilars market. Growth will be fastest in the first half of the forecast period, driven by the launch of the first products in developed markets, as well as the continued launch of biosimilar mAbs in emerging markets.”
The 204-page report contains 72 tables and 72 figures that add visual analysis in order to explain the developing trends within the Global Biosimilar Monoclonal Antibodies Market.
Visiongain provides revenue forecasts for the period 2017-2027 and qualitative analyses for the Global Biosimilar Monoclonal Antibodies market as well as these submarkets: Infliximab, Rituximab, Abciximab, Trastuzumab. Adalimumab and Bevacizumab
This report also provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the leading individual biosimilar mAb products. This report provides profiles of 10 leading companies either with biosimilar mAbs already on the market or in the pipeline. Moreover, our study discusses strengths, weaknesses, opportunities and threats affecting the biosimilar monoclonal antibodies market
The 204-page report offers market forecasts for the US, Japan, EU5, BRIC, South Korea and the Rest of the World.
The report Global Biosimilar Monoclonal Antibodies Forecast 2017-2027: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab report will be of value to anyone who wants to better understand the biosimilar monoclonal antibodies market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the biosimilar monoclonal antibodies industry.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market for ophthalmic drugs is a growing one.
17 June 2019
Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.
14 June 2019
The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.
06 June 2019
Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.